← Back to Home

First Oral PCSK9 Inhibitor Wins FDA Approval, Taking Cholesterol Treatment Beyond the Injection Barrier

Lipfendra brings a powerful class of lipid-lowering drugs, previously administered mostly by injection, into the oral era; it can sharply lower LDL-C, but whether cardiovascular event risk falls in parallel still awaits answers from a large outcomes trial.

By SURL BioNews

For many patients with high cholesterol, the difficulty of treatment lies not only in the cholesterol numbers themselves, but also in whether long-term medication can fit into daily life. After the U.S. FDA approved Merck’s Lipfendra (enlicitide), PCSK9 inhibitors have an oral option for the first time, opening a new route of administration for adult patients who need further reductions in low-density lipoprotein cholesterol (LDL-C).

The FDA said Lipfendra may be used as an adjunct to diet and exercise in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Merck explained that the drug is a 20 mg tablet taken once daily and is a novel macrocyclic peptide that can bind PCSK9 and prevent it from interacting with LDL receptors, allowing the liver to maintain its ability to clear LDL-C from the blood.

The PCSK9 pathway is not a new concept. Existing PCSK9 inhibitors already have a place in high-risk lipid-lowering treatment, but most are injectable formulations; the Associated Press noted in a same-day report that price, insurance restrictions, and prescribing and use hurdles had previously suppressed broader adoption of this class of drugs. An oral drug will not automatically solve all access issues, but it may change the starting point for discussions between physicians and patients about intensifying lipid-lowering treatment.

This approval was based primarily on two randomized, double-blind, placebo-controlled Phase 3 trials that enrolled a total of 3,207 adults. The CORALreef Lipids trial included 2,904 patients with hypercholesterolemia, some with HeFH, and with a history of atherosclerotic cardiovascular disease or higher risk; CORALreef HeFH enrolled 303 patients with HeFH. Both trials compared once-daily Lipfendra with placebo on top of existing stable lipid-lowering therapy.

At Week 24, Lipfendra reduced LDL-C by 56% and 59%, respectively, compared with placebo. Merck also reported reductions in non-high-density lipoprotein cholesterol and apolipoprotein B; these markers are associated with atherosclerosis risk. However, these data remain lipid surrogate endpoints and cannot yet be equated with proof of reductions in myocardial infarction, stroke, or death.

On safety, the FDA said the incidence of adverse reactions in the first trial was similar to placebo; in the HeFH trial, diarrhea and dizziness were more common than with placebo. Data released by Merck showed that among patients with HeFH, diarrhea occurred in 7% of the Lipfendra group and 2% of the placebo group, while dizziness occurred in 9% versus 4%; discontinuation rates due to adverse reactions were similar in the two trials. The Associated Press also mentioned that the drug must be taken on an empty stomach, and real-world adherence will still affect clinical experience.

The next key question for Lipfendra is whether the scale of lipid reduction can translate into hard clinical outcomes. Merck said the CORALreef Outcomes cardiovascular outcomes trial has completed enrollment of more than 14,500 participants; before results are released, both FDA and company materials clearly state that it is currently uncertain whether enlicitide can reduce cardiovascular morbidity or mortality. This approval therefore looks like an important entry point rather than an endpoint: it brings PCSK9 therapy closer to the form of everyday medication, while also pushing the responsibility for proving long-term clinical benefit into the next stage.

References

  1. FDA
  2. Merck
  3. Conexiant
  4. Associated Press